New hope for tough cancers: experimental drug DPTX3186 enters first human trial
NCT ID NCT07312903
First seen Jan 04, 2026 · Last updated Jun 23, 2026 · Updated 26 times
Summary
This early-stage study tests an experimental oral drug called DPTX3186 in 40 adults with advanced solid tumors (like colorectal, gastric, lung, or triple-negative breast cancer) that are linked to a specific cell signal called Wnt. These participants have no other approved treatments left. The main goal is to check the drug's safety and how the body processes it, not yet to prove it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
NEXT San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DPTX3186 (an experimental oral drug)
What this could lead to
If it works, this could point toward a new treatment option for certain hard-to-treat cancers that have run out of standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 40 participants, so the main goal is safety, not effectiveness. Many drugs fail at this stage, and side effects are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.